Structural Drivers of Bipolar Spectrum Overclassification: How Insomnia-Related States Can Be Classified as Mania

#mentalhealth #psychiatry #bipolardisroder #insomnia

Abstract

Psychiatric diagnostic frameworks rely on descriptive symptom clusters rather than etiological differentiation, a design choice that carries predictable consequences under conditions of time compression, liability asymmetry, and insurance-driven classification requirements. This paper examines how insomnia-related states—particularly those involving REM sleep disruption, compensatory hyperarousal, and sustained cognitive engagement—can enter manic diagnostic pathways despite differing underlying mechanisms. Drawing on sleep science, diagnostic literature, and institutional incentive analysis, the paper maps how reduced sleep duration, elevated activity, and productivity may be interpreted within manic symptom criteria absent sufficient contextual reconstruction. The analysis does not dispute the clinical reality of bipolar disorder, nor does it assess individual diagnostic decisions. Instead, it identifies structural conditions under which diagnostic convergence may occur, contributing to bipolar spectrum overclassification in sleep-deprived populations. Implications are discussed in terms of diagnostic restraint, category lock-in effects, and the limits of descriptive classification systems under risk-averse clinical practice.

I. Insomnia and Bipolar Disorder: Physiological States and Descriptive Classification

Insomnia is not merely a secondary symptom of psychiatric illness but a primary neurophysiological condition with distinct and well-documented cognitive, affective, and behavioral consequences. Contemporary sleep research characterizes insomnia as a disorder of chronic hyperarousal involving dysregulation across autonomic, endocrine, and central nervous system domains (Riemann et al., 2010; Van Someren, 2021). Individuals with insomnia commonly exhibit elevated cortisol levels, increased sympathetic nervous system activity, altered dopaminergic signaling, and persistent disruption of sleep architecture, particularly involving rapid eye movement (REM) sleep (Roehrs & Roth, 2019; Riemann et al., 2023).

These physiological features produce predictable downstream effects. Sleep fragmentation and REM disruption impair emotional regulation, executive function, and cognitive flexibility while simultaneously promoting compensatory states of heightened alertness or overactivation (Thompson et al., 2022; Mehta et al., 2020). In high-functioning individuals, this compensatory hyperarousal may temporarily sustain productivity and goal-directed activity despite mounting physiological exhaustion. Such states are often episodic, culminating in forced recovery periods characterized by prolonged sleep and delayed normalization of circadian rhythms (Van Someren, 2021).

Importantly, these insomnia-related states can present behaviorally with reduced sleep duration, increased activity, intensified focus, and affective variability—features that overlap substantially with the descriptive criteria used to identify manic or hypomanic episodes in psychiatric classification systems. This overlap is not incidental but arises from shared reliance on observable behavioral markers rather than underlying mechanisms.

Bipolar disorder, as operationalized in contemporary psychiatric practice, is defined descriptively rather than etiologically. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) explicitly organizes bipolar spectrum diagnoses around clusters of observable symptoms, including changes in sleep, energy, activity level, mood, and cognition, without reference to biomarkers or causal pathways (American Psychiatric Association, 2022; First, 2022). While this descriptive approach enhances inter-rater reliability, it does not provide a mechanism for distinguishing between distinct physiological states that may produce similar outward behaviors (Regier et al., 2013).

As a result, diagnostic differentiation between primary mood disorders and sleep-driven dysregulation depends heavily on contextual reconstruction, longitudinal observation, and interpretation of subjective reports—processes that are vulnerable to compression and distortion in real-world clinical settings. The absence of biological markers capable of distinguishing insomnia-related hyperarousal from mood pathology further constrains diagnostic certainty (Hyndych et al., 2025).

The convergence between insomnia-related behavioral states and bipolar diagnostic criteria therefore reflects a structural feature of the classification system rather than an anomaly. Reduced sleep, increased goal-directed activity, and affective lability function simultaneously as indicators of sleep deprivation and as diagnostic signals within manic or hypomanic frameworks. Without etiological differentiation, these features remain diagnostically ambiguous by design.

This ambiguity is foundational to the analysis that follows. The issue examined in this paper is not whether bipolar disorder exists as a legitimate and often severe psychiatric condition, nor whether insomnia may co-occur with mood disorders. Rather, it is how insomnia-related physiological states—particularly those involving REM disruption and compensatory hyperarousal—can be absorbed into bipolar diagnostic pathways under descriptive classification systems lacking causal resolution.

By establishing insomnia as an independent neurophysiological condition and bipolar disorder as a symptom-defined category, this section delineates the structural conditions under which diagnostic convergence becomes likely. Subsequent sections examine how pharmacological interventions, institutional diagnostic constraints, and evidentiary standards interact with this convergence to produce downstream risk and accountability gaps.

II. Premature Diagnostic Closure Under Conditions of Known Uncertainty

The contemporary breadth of bipolar spectrum diagnosis did not emerge in a vacuum. Over the past several decades, the operational boundaries of bipolar disorder have expanded alongside the proliferation of psychiatric pharmacological interventions indicated for mood stabilization, agitation, sleep disturbance, and affective instability. As diagnostic categories broadened across successive editions of the Diagnostic and Statistical Manual of Mental Disorders, bipolar disorder increasingly came to function as a flexible classification capable of encompassing a wide range of behavioral and sleep-related presentations (American Psychiatric Association, 2022; Regier et al., 2013; First, 2022).

This expansion coincided with the development and widespread clinical adoption of pharmacological agents marketed for mood stabilization, relapse prevention, and behavioral regulation. Within this context, diagnostic classification and pharmacological intervention became structurally linked: bipolar diagnoses served not only as descriptive labels but also as gateways to established medication pathways. The result was a clinical environment in which broad symptom clusters—particularly those involving sleep disruption, heightened activity, and affective variability—were increasingly interpretable within bipolar frameworks, even in the absence of etiological differentiation.

Importantly, this linkage does not require intentional overdiagnosis to function. Diagnostic systems that are descriptive rather than causal naturally align with treatment models organized around symptom suppression rather than mechanism resolution. As bipolar disorder became associated with a growing range of pharmacological options, the threshold for classification under bipolar spectrum categories effectively lowered, particularly in settings where rapid clinical decision-making was prioritized.

Within this expanded diagnostic landscape, psychiatric diagnosis frequently occurs under conditions of incomplete information, time constraint, and unresolved causal ambiguity. Although these limitations are widely acknowledged in principle, they do not consistently produce diagnostic restraint in practice. Instead, bipolar spectrum classifications are often rendered at first clinical contact, even when known confounding variables such as insomnia, neurological injury, or acute sleep deprivation are present.

This pattern reflects a form of premature diagnostic closure: the assignment of a categorical diagnosis before alternative explanatory variables have been adequately differentiated over time. In contexts where diagnostic categories are explicitly descriptive rather than etiological, such closure exceeds what available evidence can reliably support.

As established in Section I, insomnia constitutes a primary neurophysiological state capable of producing behavioral and affective presentations that overlap substantially with manic or hypomanic descriptors, including reduced sleep duration, increased activity, intensified focus, emotional lability, and episodic productivity (Riemann et al., 2010; Van Someren, 2021; Thompson et al., 2022). Neurological injury further compounds this ambiguity, as brain injury is independently associated with dysregulation of affect, impulse control, sleep–wake cycles, and executive functioning—domains central to mood disorder assessment.

Despite the presence of such confounders, diagnostic practice often proceeds as though they do not materially alter the evidentiary threshold required for classification. Bipolar diagnoses may be assigned during initial evaluations without longitudinal observation, sleep stabilization, or causal sequencing, even though the diagnostic framework itself provides no mechanism for distinguishing sleep-driven dysregulation from primary mood pathology at a single time point (American Psychiatric Association, 2022; Regier et al., 2013).

This represents a structural contradiction. On the one hand, psychiatric classification systems acknowledge the absence of biomarkers and rely on behavioral observation and clinical judgment. On the other hand, diagnostic certainty is frequently asserted before sufficient temporal data exist to justify it. When multiple plausible etiologies exist for a behavioral presentation, and when available diagnostic categories are descriptive rather than causal, immediate classification constitutes epistemic overreach rather than clinical certainty.

Longitudinal observation is not an ancillary refinement in such cases; it is the only method available for differentiation. Sleep-related dysregulation, medication effects, neurological sequelae, and primary mood disorders may converge behaviorally in the short term while diverging meaningfully over time. Without allowing for this divergence to be observed, diagnostic conclusions remain provisional by necessity—even if they are operationalized as definitive in clinical records.

The consequences of premature closure extend beyond nomenclature. Diagnostic classification functions as a gateway decision that shapes subsequent interpretation of symptoms, selection of interventions, and attribution of causality. Once a bipolar spectrum label is applied, subsequent behavioral changes are more likely to be interpreted as illness progression rather than as evidence warranting diagnostic reassessment (First, 2022). This dynamic, commonly described as category lock-in, reduces the likelihood that initial uncertainty will be revisited.

The tendency toward rapid diagnostic closure cannot be explained solely by individual clinician behavior. It arises within institutional contexts that prioritize risk containment, documentation efficiency, and treatment pathway alignment over etiological resolution. These pressures are examined in detail in Section IV. The purpose of the present section is not to assign blame, but to establish that current diagnostic practices frequently diverge from what existing knowledge about insomnia, neurological injury, and causal ambiguity would warrant.

In sum, the routine assignment of bipolar diagnoses at first contact—particularly in the presence of known destabilizing conditions such as insomnia or brain injury—reflects a procedural mismatch between what psychiatric knowledge requires and what institutional practice permits. This mismatch establishes the conditions under which pharmacological intervention is initiated in the absence of causal clarity, setting the stage for the downstream effects examined in subsequent sections.

III. Side Effects of Psychiatric Drugs and Symptom Mimicry

Psychiatric medications exert their clinical effects by altering neurochemical systems that regulate mood, cognition, arousal, impulse control, and sleep. These same systems form the basis of psychiatric symptom classification. As a result, overlap between medication effects and psychiatric symptom descriptors is not incidental but structurally inevitable.

Antidepressants, antipsychotics, and mood stabilizers primarily modulate serotonergic, dopaminergic, noradrenergic, glutamatergic, and GABAergic pathways—systems responsible for affective tone, executive function, psychomotor activity, and circadian regulation (Wilson & Argyropoulos, 2005; Wichniak et al., 2017). Alteration of these systems predictably produces changes in behavior and subjective experience that resemble psychiatric syndromes, including emotional blunting, agitation, restlessness, cognitive slowing, insomnia or hypersomnia, and affective instability.

Because psychiatric diagnosis relies on behavioral observation rather than biological markers, these pharmacologically induced states are frequently indistinguishable from the conditions they are presumed to treat. This creates an epistemic vulnerability: once medication exposure begins, subsequent behavioral changes cannot be reliably attributed to illness progression, medication effects, or physiological adaptation to treatment.

Sleep architecture disruption and false stabilization

Sleep-related effects are among the most consistently documented consequences of psychiatric drug use. Antidepressants are well established to suppress rapid eye movement (REM) sleep, alter REM latency, and fragment sleep architecture, even when they produce subjective sedation (Wilson & Argyropoulos, 2005; Matsuda et al., 2021; Crișan et al., 2023). Second-generation antipsychotics similarly disrupt sleep continuity and REM expression, often creating non-restorative sleep states that may be misinterpreted as clinical improvement due to behavioral quieting or reduced agitation (Monti et al., 2017; Gedge et al., 2010).

In individuals with preexisting insomnia or circadian dysregulation, these effects are particularly consequential. Sedation may reduce outward signs of distress while simultaneously worsening underlying sleep pathology. In such cases, apparent stabilization reflects behavioral suppression rather than resolution of the destabilizing process.

Symptom mimicry beyond sleep

Psychiatric medications also produce affective and cognitive changes that map directly onto diagnostic symptom criteria. Emotional blunting associated with serotonergic agents may resemble depressive flattening. Dopamine antagonism may produce psychomotor slowing, reduced motivation, and cognitive impairment that resemble negative or depressive symptoms. Conversely, antidepressant-induced agitation, anxiety, or sleep disruption may resemble hypomanic or mixed states (Wichniak et al., 2017; Patel et al., 2015).

These effects are not rare adverse events; they are expected pharmacodynamic outcomes. When such changes occur after diagnostic labeling, they are routinely interpreted as confirmation of the underlying disorder rather than as medication-induced phenomena.

Akathisia as a paradigmatic case of symptom mimicry

Akathisia illustrates the diagnostic consequences of pharmacological symptom mimicry with particular clarity. Characterized by intense inner restlessness, agitation, anxiety, dysphoria, and an often overwhelming urge to move, akathisia is a well-documented adverse effect of antipsychotic and some antidepressant medications (Bratti et al., 2007; Salem et al., 2017; Pringsheim et al., 2018).

Behaviorally, akathisia may present as pacing, flight behavior, irritability, emotional distress, or apparent aggression—features that are frequently misinterpreted as worsening psychiatric illness rather than as drug-induced neurophysiological states. Importantly, akathisia is also associated with elevated suicide risk and emergency presentations, including crisis calls and involuntary interventions (Salem et al., 2017).

In emergency or crisis-response contexts, akathisia-related agitation may be interpreted through threat-management frameworks rather than etiological analysis. Escalation to physical restraint or law enforcement involvement may occur rapidly, particularly when behavioral distress is misread as intent rather than as iatrogenic dysregulation. Once force is introduced, subsequent clinical and legal interpretations tend to align with the initial threat framing, further obscuring causal origins.

Withdrawal, rebound, and attribution collapse

Withdrawal and rebound phenomena further confound diagnostic interpretation. Many psychiatric medications produce delayed withdrawal effects, including insomnia, anxiety, irritability, agitation, mood lability, and cognitive disturbance, which may emerge weeks or months after dose reduction or discontinuation (Wilson & Argyropoulos, 2005; Wichniak et al., 2017). Behaviorally, these presentations are often indistinguishable from relapse or illness recurrence.

In practice, withdrawal-related symptoms are frequently interpreted as confirmation of the original diagnosis rather than as evidence of medication-induced dependency or neuroadaptation. This interpretive asymmetry reinforces diagnostic closure and justifies continued pharmacological intervention, even as causal clarity deteriorates.

Loss of baseline and irreversible uncertainty

Once psychiatric medications are introduced, the individual’s untreated baseline state becomes irretrievable. Subsequent observations occur against a background of altered neurochemistry, modified sleep architecture, and medication interactions. At this stage, differentiation between primary illness, medication effect, and withdrawal becomes structurally impossible.

This loss of baseline produces a paradoxical outcome: diagnostic confidence may increase over time despite decreasing epistemic certainty. What appears clinically as confirmation may, in fact, reflect progressive entanglement between pharmacological effects and behavioral interpretation.

Implications for diagnostic restraint

The purpose of this section is not to argue against psychiatric medication use categorically. Many individuals derive meaningful benefit from pharmacological treatment. Rather, the issue is that when medication effects are behaviorally indistinguishable from psychiatric symptoms, and when diagnostic categories are descriptive rather than causal, the evidentiary threshold for diagnosis and intervention must rise rather than fall.

Absent such restraint, pharmacological intervention becomes a source of diagnostic noise that amplifies uncertainty while simultaneously foreclosing its resolution. This dynamic is especially consequential in populations with preexisting sleep dysregulation or neurological vulnerability. The institutional mechanisms that permit—and normalize—this outcome are examined in the following sectio

IV. The Mechanism of Psychiatric Diagnosis Under Constraint

Psychiatric diagnosis does not occur in a neutral epistemic environment. It is shaped by institutional constraints that prioritize speed, risk containment, documentation compliance, and treatment pathway alignment over etiological resolution. These constraints materially influence how uncertainty is managed—and, critically, how quickly it is closed.

Clinical psychiatric evaluations are frequently conducted under severe time compression, particularly in outpatient, emergency, and crisis-response settings. Initial assessments may last minutes rather than hours and are often expected to yield a working diagnosis sufficient to justify immediate intervention. In such contexts, diagnostic categories that are broad, behaviorally defined, and treatment-linked become functionally advantageous.

Bipolar spectrum diagnoses occupy this role. As descriptive categories anchored to observable changes in sleep, activity, mood, and behavior, they can be applied rapidly without requiring longitudinal data or causal differentiation. Once applied, they authorize established pharmacological pathways and satisfy documentation and billing requirements (American Psychiatric Association, 2022; Regier et al., 2013).

This diagnostic efficiency comes at an epistemic cost. Conditions such as insomnia, medication effects, withdrawal phenomena, and neurological injury—each capable of producing overlapping behavioral presentations—require time and contextual reconstruction to differentiate. Under institutional pressure, that time is rarely available.

Risk asymmetry and defensive classification

A central driver of premature diagnostic closure is risk asymmetry. From an institutional standpoint, the perceived cost of under-diagnosing mania or bipolar disorder is significantly higher than the cost of over-diagnosing it. Missed diagnoses are associated with fears of psychosis, self-harm, hospitalization, and legal liability. Over-diagnosis, by contrast, is generally treated as a correctable or benign error.

This asymmetry incentivizes defensive classification. When faced with behavioral activation, sleep disturbance, agitation, or affective instability, clinicians are structurally encouraged to err on the side of categorical certainty rather than provisional ambiguity. Diagnostic restraint, while epistemically appropriate, is institutionally disfavored.

Diagnostic labels as gateway decisions

Psychiatric diagnoses do more than describe; they gate downstream interpretation. Once a bipolar spectrum label is entered into the clinical record, it becomes the dominant explanatory framework through which subsequent behavior is interpreted. New symptoms are evaluated as manifestations of the underlying disorder rather than as signals warranting reassessment.

This process—often described as category lock-in—reduces diagnostic flexibility over time. Behavioral changes that might otherwise prompt causal reevaluation are instead assimilated into illness narratives, reinforcing the original classification (First, 2022). In this way, diagnostic certainty may increase even as the evidentiary basis for that certainty weakens.

Interaction with pharmacological intervention

The diagnostic mechanism described above interacts synergistically with pharmacological practice. As shown in Section III, psychiatric medications can produce behavioral and cognitive effects that closely resemble psychiatric symptoms. Once medication exposure begins, clinicians must interpret changes against a moving baseline shaped by drug effects, side effects, and withdrawal phenomena.

However, institutional diagnostic frameworks lack formal mechanisms for re-separating these effects from illness progression. Medication-induced agitation may be read as worsening mania; sedation may be read as stabilization; withdrawal symptoms may be read as relapse. Each interpretation further entrenches the original diagnosis and justifies continued intervention.

Emergency and crisis contexts

These dynamics are intensified in emergency and crisis-response settings, where law enforcement and psychiatric systems intersect. In such contexts, behavioral dysregulation is often interpreted through threat and control frameworks rather than etiological analysis. Diagnostic nuance becomes secondary to immediate containment.

When medication-induced states such as akathisia or severe anxiety present as agitation or flight behavior, escalation may occur rapidly. Once force or restraint is introduced, subsequent diagnostic and legal interpretations tend to align with the initial threat framing, further obscuring causal origins.

Institutional normalization of uncertainty suppression

Importantly, none of these dynamics require individual malice, incompetence, or bad faith. They emerge from systems optimized for throughput, risk avoidance, and procedural defensibility rather than causal truth. Uncertainty is not resolved; it is suppressed through classification.

The result is a diagnostic environment in which restraint is structurally discouraged, provisionality is rapidly abandoned, and irreversible interventions are introduced under conditions of unresolved ambiguity. This environment does not merely permit premature diagnostic closure—it actively produces it.

The consequences of this mechanism are not theoretical. Once diagnostic closure and pharmacological intervention occur together, causal attribution collapses, baseline states are lost, and accountability becomes diffuse. These downstream effects are examined directly in the following section.

V. Pharmacological Harm in Insomnia-Vulnerable Populations

Pharmacological intervention following premature diagnostic closure carries differential risk across patient populations. Individuals with primary insomnia, circadian dysregulation, or neurological vulnerability represent a particularly exposed group, not because psychiatric medications are inherently harmful, but because the interaction between sleep pathology and psychotropic effects amplifies instability while obscuring causation.

Insomnia is characterized by chronic hyperarousal, impaired emotional regulation, and disrupted sleep architecture, particularly involving REM sleep (Riemann et al., 2010; Van Someren, 2021). These features already compromise cognitive flexibility, impulse regulation, and stress tolerance. When psychiatric medications are introduced into this physiological context, their effects do not occur on a neutral substrate but interact with an already destabilized system.

Sleep disruption as a harm multiplier

As established in Section III, many psychiatric medications suppress REM sleep, fragment sleep continuity, or alter circadian timing, even when they produce subjective sedation (Wilson & Argyropoulos, 2005; Matsuda et al., 2021; Monti et al., 2017). In individuals without baseline sleep pathology, these effects may be tolerable or transient. In individuals with chronic insomnia, however, further disruption of sleep architecture may exacerbate emotional lability, cognitive impairment, and autonomic dysregulation.

This creates a paradoxical treatment dynamic. Sedation may reduce visible distress or agitation, leading to the appearance of stabilization, while underlying sleep pathology worsens. Because psychiatric assessment relies heavily on observable behavior, this apparent improvement may be misinterpreted as therapeutic success even as physiological instability deepens.

Cognitive and affective impairment in high-functioning individuals

Psychotropic medications are also associated with cognitive side effects, including reduced processing speed, impaired working memory, diminished executive function, and emotional blunting (Wichniak et al., 2017; Monti et al., 2017). In individuals whose baseline functioning depends on sustained cognitive engagement, these effects may represent substantial functional harm even in the absence of overt behavioral deterioration.

Importantly, such impairments may not register as clinical deterioration within psychiatric frameworks focused on symptom suppression. Reduced activity, emotional flattening, or behavioral quieting may be interpreted as stabilization rather than as loss of function. For insomnia-vulnerable individuals, this tradeoff may be particularly pronounced, as cognitive compensation often masks the severity of underlying sleep deprivation until collapse occurs.

Escalation through side-effect reinterpretation

When medication side effects produce agitation, restlessness, anxiety, or sleep disruption, these effects are frequently interpreted as evidence of illness severity rather than as adverse reactions, particularly once a bipolar spectrum diagnosis has been applied (First, 2022). In insomnia-vulnerable populations, this reinterpretation can initiate escalation cycles in which additional medications are layered to address symptoms that are themselves iatrogenic.

Akathisia exemplifies this process. As discussed in Section III, akathisia produces intense agitation, distress, and behavioral dysregulation that may be indistinguishable from psychiatric decompensation (Bratti et al., 2007; Salem et al., 2017). In individuals with preexisting insomnia or anxiety, akathisia may precipitate emergency presentations, involuntary interventions, or law-enforcement involvement. These outcomes represent not isolated adverse events but predictable consequences of pharmacological exposure under diagnostic uncertainty.

Loss of agency and forced treatment trajectories

Once pharmacological escalation occurs, insomnia-vulnerable individuals may experience progressive loss of agency over their own treatment trajectory. Behavioral responses to medication effects—such as agitation, withdrawal, or noncompliance—are often interpreted as illness-driven rather than as rational responses to intolerable states. This interpretive framework reduces opportunities for reassessment and increases the likelihood of coercive or involuntary interventions.

From a systems perspective, these outcomes are not aberrations. They arise from the interaction between descriptive diagnosis, pharmacological symptom mimicry, and institutional risk management practices. Individuals with insomnia are disproportionately affected because their baseline physiological instability magnifies drug effects while simultaneously making those effects harder to distinguish from psychiatric pathology.

Harm without attribution

Crucially, the harms described here are not readily attributable to identifiable errors or actors. Cognitive impairment, sleep destabilization, emotional blunting, emergency escalation, and functional decline may occur without clear temporal boundaries or singular causal events. As a result, harm accumulates without triggering corrective mechanisms.

This absence of attribution does not negate harm; it normalizes it. When adverse outcomes cannot be clearly separated from illness progression, they are absorbed into diagnostic narratives rather than recognized as consequences of intervention. For insomnia-vulnerable populations, this dynamic transforms uncertainty into exposure and exposure into entrenchment.

Implications

The harms outlined in this section are not inevitable consequences of psychiatric care. They arise under specific conditions: premature diagnostic closure, pharmacological intervention without causal differentiation, and the absence of structural restraint in insomnia-vulnerable individuals. Recognizing these conditions does not require rejecting psychiatric treatment, but it does require acknowledging that current diagnostic and prescribing practices expose certain populations to disproportionate and foreseeable risk.

The final section examines why these harms rarely translate into accountability, remediation, or systemic correction, despite their recurrence and documentation.

VI. Evidentiary Collapse, Liability Standards, and the Absence of Accountability

The harms described in preceding sections rarely translate into formal accountability, remediation, or systemic correction. This is not because harm is uncommon or undocumented, but because the evidentiary standards required to establish causation are incompatible with the structure of psychiatric diagnosis and pharmacological intervention once treatment begins.

Absence of causal biomarkers

Psychiatric diagnosis lacks objective biomarkers capable of distinguishing primary illness from medication effects, withdrawal phenomena, or sleep-driven dysregulation. Diagnostic determinations are based on behavioral observation, clinical judgment, and patient report—precisely the domains most altered by psychotropic drugs and sleep disruption (American Psychiatric Association, 2022; Regier et al., 2013). In legal and administrative contexts, this absence of objective markers renders causal attribution inherently unstable.

Courts and oversight bodies require demonstrable links between action and outcome. In psychiatry, once medication exposure occurs, the same behaviors may plausibly be attributed to illness progression, adverse effects, withdrawal, or comorbid conditions. Without a reliable method to disaggregate these possibilities, causation cannot be established to evidentiary standards.

Destruction of baseline and confounding by intervention

Pharmacological intervention irreversibly alters the evidentiary landscape. As shown in Section III, psychiatric drugs modify neurochemistry and sleep architecture in ways that produce behavioral changes indistinguishable from psychiatric symptoms (Wilson & Argyropoulos, 2005; Wichniak et al., 2017). Once treatment begins, the individual’s untreated baseline state becomes unrecoverable.

From an evidentiary standpoint, this constitutes confounding by intervention. Subsequent deterioration, instability, or functional decline cannot be cleanly attributed to either the underlying condition or the treatment itself. Even longitudinal data become ambiguous, as medication effects and withdrawal phenomena may unfold over extended timeframes and vary across individuals (Matsuda et al., 2021; Crișan et al., 2023).

Diagnostic labels as alternative explanations

Psychiatric diagnoses function as legally robust alternative explanations. Once a bipolar spectrum diagnosis is recorded, it provides a standing rationale for a wide range of adverse outcomes, including agitation, cognitive impairment, sleep disruption, emergency presentations, and behavioral dysregulation. In legal contexts, this diagnostic label often supersedes competing causal narratives.

Adverse effects are reframed as expected manifestations of illness severity. Withdrawal symptoms are reframed as relapse. Functional decline is reframed as disease progression. This interpretive elasticity makes it exceedingly difficult to demonstrate that harm arose from intervention rather than from the diagnosed condition itself (First, 2022).

Withdrawal as retrospective validation

Withdrawal phenomena present a particularly intractable evidentiary problem. Symptoms emerging after dose reduction or discontinuation—such as insomnia, anxiety, agitation, mood lability, and cognitive disturbance—are behaviorally indistinguishable from relapse and are frequently cited as retrospective confirmation of the original diagnosis (Wichniak et al., 2017; Patel et al., 2015).

This creates a closed evidentiary loop: medication produces dependency or neuroadaptation; withdrawal produces distress; distress is interpreted as illness; illness justifies continued treatment. Within this loop, the possibility of iatrogenic harm is systematically displaced.

Liability asymmetry and institutional incentives

Accountability is further undermined by liability asymmetry. The perceived legal and professional risks associated with under-diagnosis or under-treatment—particularly of bipolar disorder—are substantially greater than those associated with over-diagnosis or pharmacological overexposure. Missed diagnoses are framed as dangerous omissions; adverse treatment outcomes are framed as unavoidable tradeoffs.

This asymmetry incentivizes defensive practice and discourages diagnostic restraint. Because harm is difficult to prove and liability is diffuse, institutional systems lack incentives to impose additional safeguards or evidentiary requirements prior to intervention.

Diffusion of responsibility

Responsibility for harm is further diffused across multiple actors and decision points. Diagnostic closure, prescribing, medication adjustment, emergency response, and legal adjudication occur within separate institutional domains, each operating under its own constraints. No single decision is sufficient to establish causation, and no single actor bears clear responsibility.

As a result, harms accumulate without triggering corrective feedback. Individuals experience real and often lasting consequences—cognitive impairment, sleep destabilization, loss of function, emergency escalation—without identifiable mechanisms for redress.

Implications: restraint as the only remaining safeguard

The absence of accountability mechanisms does not imply the absence of harm. It implies the absence of proof under existing standards. Where causal attribution is structurally unattainable and intervention irreversibly obscures evidence, restraint becomes the only ethically coherent safeguard.

This restraint must occur upstream, prior to pharmacological entanglement and diagnostic lock-in. Once intervention proceeds under unresolved uncertainty, the system loses its capacity to distinguish care from harm, treatment from cause, and protection from exposure.

The conclusion that follows does not propose novel diagnostics or reject psychiatric treatment. It argues that where certainty cannot be established and accountability cannot function, restraint is not optional—it is required by the limits of knowledge itself.

Conclusion — Diagnostic Power Requires Procedural Restraint

This paper has examined how insomnia-related physiological states can be classified as mania under contemporary psychiatric practice, and how that classification—once operationalized through pharmacological intervention—can produce irreversible epistemic, clinical, and legal consequences. The analysis has shown that this outcome does not arise from individual negligence or isolated error, but from the interaction of descriptive diagnostic frameworks, pharmacological symptom mimicry, institutional risk incentives, and evidentiary limits that foreclose later correction.

Insomnia is a primary neurophysiological condition capable of producing behavioral presentations that overlap substantially with manic and hypomanic descriptors. Bipolar disorder, as currently operationalized, is a descriptive category that relies on those same observable behaviors while explicitly lacking etiological differentiation. Under these conditions, accurate diagnosis requires time, contextual reconstruction, and longitudinal observation. Yet psychiatric practice routinely proceeds in the opposite direction: diagnostic certainty is asserted early, often at first contact, even when known confounders such as sleep dysregulation or neurological injury are present.

Once diagnostic closure occurs and pharmacological intervention begins, causal attribution collapses. Psychiatric drugs alter sleep architecture, cognition, affect, and arousal in ways that are behaviorally indistinguishable from psychiatric illness. Withdrawal and rebound phenomena further confound interpretation. Baseline states become unrecoverable. Subsequent deterioration or instability can be plausibly attributed to illness progression, treatment effects, or physiological adaptation, but cannot be definitively assigned to any one cause. At this point, accountability becomes structurally unattainable.

These dynamics create a system in which harm can occur without provability, and provability is a prerequisite for correction. In such a system, ethical responsibility cannot be enforced downstream. It must be exercised upstream.

The solution, therefore, is not diagnostic expansion, novel pharmacology, or increased confidence in early classification. It is procedural restraint under conditions of known uncertainty.

Where insomnia, circadian disruption, neurological injury, or other destabilizing conditions are present, immediate classification within bipolar diagnostic frameworks exceeds what descriptive criteria alone can justify. In these contexts, restraint is not optional and it is not a matter of clinical preference. It is required by basic principles of causal reasoning.

Specifically, psychiatry must distinguish between diagnostic availability and diagnostic entitlement. The ability to assign a label does not constitute sufficient justification to do so when alternative explanations remain unresolved and when intervention irreversibly alters the evidentiary landscape. Longitudinal observation, sleep-focused differentiation, and explicit acknowledgment of provisionality are not refinements to best practice; they are the minimum safeguards necessary to prevent avoidable harm in the absence of biomarkers.

Importantly, this position does not deny the reality or severity of bipolar disorder, nor does it argue against pharmacological treatment when clearly indicated. It argues that when certainty cannot be established and accountability cannot function, the threshold for irreversible action must rise, not fall. Diagnostic humility is not a concession to uncertainty; it is the only rational response to it.

Psychiatry already acknowledges its descriptive limits. What is required now is alignment between that acknowledgment and clinical practice. Until restraint is treated as a structural requirement rather than a discretionary option, the system will continue to convert uncertainty into exposure and exposure into entrenchment—without the means to distinguish care from harm.

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.; DSM-5-TR). American Psychiatric Publishing.

Bratti, I. M., Kane, J. M., & Marder, S. R. (2007). Chronic restlessness with antipsychotics. American Journal of Psychiatry, 164(11), 1648–1654. https://doi.org/10.1176/appi.ajp.2007.07071150

Crișan, C. A., Chiriac, V. F., & Cozma, L. C. (2023). REM sleep deprivation: Neurobiological mechanisms and clinical implications. Brain Sciences, 13(2), 215. https://doi.org/10.3390/brainsci13020215

First, M. B. (2022). DSM-5-TR: Overview of what’s new and what’s changed. World Psychiatry, 21(2), 169–170. https://doi.org/10.1002/wps.20962

Gedge, L., Lazowski, L., Murray, D., et al. (2010). Effects of quetiapine on sleep architecture in patients with bipolar disorder. Journal of Clinical Psychopharmacology, 30(4), 456–458. https://doi.org/10.1097/JCP.0b013e3181e5c4c9

Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5), 385–396. https://doi.org/10.2165/00002018-200629050-00003

Hyndych, A., Monti, J. M., & Monti, D. (2025). Sleep and psychiatric disorders: Bidirectional interactions and clinical implications. Frontiers in Psychiatry, 16, 1279864. https://doi.org/10.3389/fpsyt.2025.1279864

Matsuda, Y., Ishikawa, A., Shibata, S., et al. (2021). Chronic antidepressant treatment suppresses rapid eye movement sleep via serotonergic mechanisms. Scientific Reports, 11, Article 18358. https://doi.org/10.1038/s41598-021-96094-0

Mehta, R., Riedner, B. A., & Tononi, G. (2020). REM sleep loss elevates noradrenergic tone and impairs cognitive-emotional regulation. Neuroscience & Biobehavioral Reviews, 118, 195–206. https://doi.org/10.1016/j.neubiorev.2020.07.019

Monti, J. M., Monti, D., & Jantos, H. (2017). The effects of second-generation antipsychotics on sleep variables in schizophrenia and bipolar disorder. Sleep Medicine Reviews, 33, 51–62. https://doi.org/10.1016/j.smrv.2016.05.001

Morse, S. J. (2011). Causation, excuse, and the insanity defense. Behavioral Sciences & the Law, 29(6), 716–742. https://doi.org/10.1002/bsl.1012

Pringsheim, T., Gardner, D., Addington, D., et al. (2018). The assessment and treatment of antipsychotic-induced akathisia. Canadian Journal of Psychiatry, 63(11), 719–729. https://doi.org/10.1177/0706743718760288

Regier, D. A., Kuhl, E. A., & Kupfer, D. J. (2013). The DSM-5: Classification and criteria changes. World Psychiatry, 12(2), 92–98. https://doi.org/10.1002/wps.20050

Riemann, D., Spiegelhalder, K., Feige, B., et al. (2010). The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Medicine Reviews, 14(1), 19–31. https://doi.org/10.1016/j.smrv.2009.04.002

Riemann, D., Baglioni, C., Bassetti, C., et al. (2023). The psychoneurobiology of insomnia: Hyperarousal and beyond. Clocks & Sleep, 5(4), 494–513. https://doi.org/10.3390/clockssleep5040030

Roehrs, T., & Roth, T. (2019). Hyperarousal in insomnia: Pre-sleep and diurnal cortisol levels. Sleep Medicine, 55, 62–69. https://doi.org/10.1016/j.sleep.2018.10.014

Salem, H., Nagpal, C., Pigott, T., & Teixeira, A. L. (2017). Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges. Current Neuropharmacology, 15(5), 789–798. https://doi.org/10.2174/1570159X14666161216121448

Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. https://doi.org/10.5664/jcsm.6470

Thompson, K. I., Chau, P., & Wager, T. D. (2022). Acute sleep deprivation disrupts emotion regulation and cognitive control. Frontiers in Behavioral Neuroscience, 16, 945661. https://doi.org/10.3389/fnbeh.2022.945661

Van Someren, E. J. W. (2021). Brain mechanisms of insomnia: New perspectives on causes and consequences. Physiological Reviews, 101(3), 995–1046. https://doi.org/10.1152/physrev.00046.2019

Wichniak, A., Wierzbicka, A., & Jernajczyk, W. (2017). Effects of antidepressants on sleep. Current Psychiatry Reports, 19(9), 63. https://doi.org/10.1007/s11920-017-0816-4

Wilson, S., & Argyropoulos, S. (2005). Antidepressants and sleep: A qualitative review of the literature. Drugs, 65(7), 927–947. https://doi.org/10.2165/00003495-200565070-00004